TransCode Therapeutics (RNAZ) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting called to order with quorum confirmed; inspector of election appointed and sworn in.
Agenda included voting on a reverse stock split proposal and an adjournment proposal.
Shareholder proposals
Proposal to authorize a reverse stock split at a ratio between 1-for-10 and 1-for-40, at the board's discretion.
Proposal to approve adjournment of the meeting if more time was needed for proxy solicitation.
Overview of voting outcomes
Both the reverse stock split and adjournment proposals were approved by a majority of votes cast.
Final vote counts to be included in meeting minutes and SEC filings.
Partial view of Summaries dataset, powered by Quartr API
Latest events from TransCode Therapeutics
- Exclusive immunotherapy license acquired; Series C Preferred Stock issued pending shareholder approval.RNAZ
Proxy Filing3 Mar 2026 - Acquisition of ABCJ, LLC grants DEFJ, LLC potential majority control, reshaping governance and risk.RNAZProxy Filing23 Dec 2025
- Registering up to $150M in securities to advance RNA cancer therapies and vaccine programs.RNAZRegistration Filing16 Dec 2025
- Acquisition and $25M investment expand pipeline, trigger board changes, and require shareholder votes.RNAZProxy Filing2 Dec 2025
- Votes sought on ratification, reverse split, and adjournment to address Nasdaq compliance.RNAZProxy Filing2 Dec 2025
- Shareholders are urged to approve a reverse split to safeguard the Nasdaq listing and company value.RNAZProxy Filing2 Dec 2025
- Vote on a reverse stock split to maintain Nasdaq listing and an adjournment proposal.RNAZProxy Filing2 Dec 2025
- Shareholders to vote on warrant-related share issuance and potential meeting adjournment.RNAZProxy Filing2 Dec 2025
- Quorum for the annual meeting is set at one-third of outstanding shares entitled to vote.RNAZProxy Filing2 Dec 2025